Research programme: adenosine A3 antagonists - Future Medicine

Drug Profile

Research programme: adenosine A3 antagonists - Future Medicine

Alternative Names: A3AR antagonists - Future Medicine

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Future Medicine
  • Class Antiasthmatics; Antineoplastics; Antivirals; Eye disorder therapies; Hepatoprotectants; Nucleosides; Small molecules
  • Mechanism of Action Adenosine A3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Cancer; Chronic obstructive pulmonary disease; Glaucoma; Middle East respiratory syndrome coronavirus; Non-alcoholic steatohepatitis; Pulmonary fibrosis; Renal failure; Zika virus infection

Most Recent Events

  • 09 Mar 2018 Future Medicine has patent protection for adenosine A3 antagonists in South Korea, USA, Australia, China, India, Europe, Japan and Canada
  • 09 Mar 2018 Preclinical trials in Asthma in South Korea (unspecified route) before March 2018
  • 09 Mar 2018 Preclinical trials in Cancer in South Korea (unspecified route) before March 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top